Renaissance Technologies’s Traws Pharma TRAW Stock Holding History

Renaissance Technologies’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,052	Closed	-$89.3K	–	3914
2024 Q4	$89.3K	Buy	+10,052	New	+$56K	﹤0.01%	3302
2024 Q3	–	Sell	-8,724	Closed	-$97.4K	–	3956
2024 Q2	$97.4K	Sell	8,724 -2,004	-19%	-$32.3K	﹤0.01%	3187
2024 Q1	$271K	Buy	10,728 +2,774	+35%	+$53.5K	﹤0.01%	3125
2023 Q4	$148K	Buy	7,954 +606	+8%	+$10.3K	﹤0.01%	3215
2023 Q3	$131K	Sell	7,348 -2,039	-22%	-$46.5K	﹤0.01%	3192
2023 Q2	$277K	Buy	9,387 +3,595	+62%	+$96.7K	﹤0.01%	3160
2023 Q1	$106K	Sell	5,792 -914	-14%	-$19.8K	﹤0.01%	3478
2022 Q4	$108K	Sell	6,706 -1,498	-18%	-$28.3K	﹤0.01%	3597
2022 Q3	$181K	Sell	8,204 -5,129	-38%	-$155K	﹤0.01%	3415
2022 Q2	$440K	Buy	13,333 +463	+4%	+$15.6K	﹤0.01%	3230
2022 Q1	$592K	Buy	12,870 +7,525	+141%	+$349K	﹤0.01%	3082
2021 Q4	$341K	Buy	+5,345	New	+$430K	﹤0.01%	3279
2021 Q2	–	Sell	-9,859	Closed	-$3.69M	–	3834
2021 Q1	$3.69M	Buy	+9,859	New	+$3.72M	﹤0.01%	1833
2020 Q3	–	Sell	-3,166	Closed	-$672K	–	3757
2020 Q2	$672K	Buy	+3,166	New	+$484K	﹤0.01%	2753
2020 Q1	–	Sell	-1,720	Closed	-$247K	–	3872
2019 Q4	$247K	Buy	1,720 +1,598	+1,310%	+$299K	﹤0.01%	3131
2019 Q3	$39K	Buy	122 +18	+17%	+$15.5K	﹤0.01%	3345
2019 Q2	$112K	Sell	104 -21	-17%	-$28.9K	﹤0.01%	3384
2019 Q1	$154K	Sell	125 -1	-0.8%	-$1.19K	﹤0.01%	3244
2018 Q4	$99K	Sell	126 -23	-15%	-$39.2K	﹤0.01%	3233
2018 Q3	$410K	Buy	149 +3	+2%	+$7.65K	﹤0.01%	2916
2018 Q2	$332K	Buy	146 +120	+462%	+$348K	﹤0.01%	2941
2018 Q1	$123K	Buy	26 +7	+37%	+$50K	﹤0.01%	3247
2017 Q4	$164K	Sell	19 -2	-10%	-$20.6K	﹤0.01%	3165
2017 Q3	$206K	Buy	21 +1	+5%	+$10.3K	﹤0.01%	2993
2017 Q2	$245K	Sell	20 -2	-9%	-$24.8K	﹤0.01%	2951
2017 Q1	$368K	Hold	22	–	–	﹤0.01%	2856
2016 Q4	$279K	Buy	22 +5	+29%	+$74.2K	﹤0.01%	2927
2016 Q3	$256K	Buy	17 +8	+89%	+$163K	﹤0.01%	3005
2016 Q2	$281K	Buy	9 +4	+80%	+$112K	﹤0.01%	2958
2016 Q1	$163K	Buy	5 +2	+67%	+$63.4K	﹤0.01%	3139
2015 Q4	$144K	Buy	3 +2	+200%	+$148K	﹤0.01%	3062
2015 Q3	$94K	Sell	1 -1	-50%	-$107K	﹤0.01%	3016
2015 Q2	$212K	Hold	2	–	–	﹤0.01%	2969
2015 Q1	$264K	Buy	2 +1	+100%	+$164K	﹤0.01%	2799
2014 Q4	$213K	Hold	1	–	–	﹤0.01%	2673
2014 Q3	$246K	Sell	1 -2	-67%	-$569K	﹤0.01%	2519
2014 Q2	$778K	Buy	+3	New	+$885K	﹤0.01%	2148

Other funds holding TRAW

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies's TRAW Position: Q1 2025 in Review

Renaissance Technologies sold out of Traws Pharma (TRAW) in Q1 2025, closing a stake of 10,052 shares — an estimated $89.3K sold.

Renaissance Technologies first reported a position in TRAW in Q2 2014 and held it in 37 quarters. The position peaked at $3.69M in Q1 2021. 19 funds tracked by Wall St. Rank hold TRAW as of Q1 2025.

Renaissance Technologies reported no remaining Traws Pharma position as of Q1 2025 after selling out during the quarter.
Renaissance Technologies sold 10,052 Traws Pharma shares in Q1 2025, an estimated $89.3K.
Renaissance Technologies first reported a position in Traws Pharma in Q2 2014 and held it in 37 quarters.
Renaissance Technologies's Traws Pharma position peaked at $3.69M in Q1 2021.
19 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.